Roquefort Therapeutics (LON:ROQ) Trading 2.3% Higher – Here’s What Happened

Roquefort Therapeutics plc (LON:ROQ)’s stock price traded up 2.3% during trading on Friday . The stock traded as high as GBX 1.40 ($0.02) and last traded at GBX 1.33 ($0.02). 1,056,811 shares traded hands during trading, a decline of 46% from the average session volume of 1,972,811 shares. The stock had previously closed at GBX 1.30 ($0.02).

Roquefort Therapeutics Trading Up 4.6%

The firm has a market capitalization of £2.14 million, a price-to-earnings ratio of -181.33 and a beta of 0.05. The firm’s 50-day moving average is GBX 1.49 and its 200 day moving average is GBX 1.67. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37.

Insider Buying and Selling at Roquefort Therapeutics

In related news, insider Stephen Paul West acquired 2,400,000 shares of the business’s stock in a transaction that occurred on Friday, July 4th. The shares were acquired at an average cost of GBX 2 per share, with a total value of £48,000. Also, insider Simon Sinclair bought 72,507 shares of Roquefort Therapeutics stock in a transaction that occurred on Friday, June 27th. The stock was bought at an average price of GBX 1 per share, with a total value of £725.07. Corporate insiders own 20.35% of the company’s stock.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.